Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
Alimentary Pharmacology & Therapeutics|February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' PerspectiveZobair M Younossi, Homie Razavi, Michael Sherman, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Medicine|July 28, 2023
High sustained virologic response rates, regardless of race or socioeconomic class, in patients treated with chronic hepatitis C in community practice using a specialized pharmacy teamSaatchi Kuwelker, Eugenia Tsai, Lily Kuo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2012
Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis CClaudio Pasquinelli, Fiona McPhee, Timothy Eley, et al.
Hepatology (Baltimore, Md.)|October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virusEric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2015
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patientsGregory T Everson, Karen D Sims, Paul J Thuluvath, et al.
Gastroenterology|July 2, 2013
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infectionPatrick Marcellin, Curtis Cooper, Luis Balart, et al.
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisK Rajender Reddy, Marc Bourlière, Mark Sulkowski, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Alimentary Pharmacology & Therapeutics|February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' PerspectiveZobair M Younossi, Homie Razavi, Michael Sherman, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Medicine|July 28, 2023
High sustained virologic response rates, regardless of race or socioeconomic class, in patients treated with chronic hepatitis C in community practice using a specialized pharmacy teamSaatchi Kuwelker, Eugenia Tsai, Lily Kuo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2012
Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis CClaudio Pasquinelli, Fiona McPhee, Timothy Eley, et al.
Hepatology (Baltimore, Md.)|October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virusEric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 17, 2015
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patientsGregory T Everson, Karen D Sims, Paul J Thuluvath, et al.
Gastroenterology|July 2, 2013
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infectionPatrick Marcellin, Curtis Cooper, Luis Balart, et al.
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysisK Rajender Reddy, Marc Bourlière, Mark Sulkowski, et al.
Pageof 16